Table 1.

Approaches to adoptive T cell immunotherapies

	Advantages	Disadvantages
TIL	Polyclonal (reduce potential for escape through antigen loss); targets from intracellular and cell surface proteins	T cell specificity generally unknown; cannot be generated for all patients; not well established for hematologic malignancies; patient specific
TCR-T	Targets derived from intracellular and cell surface proteins; defined specificity	HLA restriction; tumor escape through antigen loss (altered processing of peptides, HLA downregulation)
CAR-T	No HLA-restriction; defined specificity	Cell surface targets only; tumor escape through antigen loss (downregulation or loss of target protein)